No distinct company-specific catalyst for 4 November is established by the information reviewed. More broadly, interest in Bioventix Plc reflects the market’s search for evidence that management can translate activity into sustainableShareholdervalue. For this business, diagnostic antibodies, assay royalties and laboratoryDemandmatter because reported progress …
No distinct company-specific catalyst for 4 November is established by the information reviewed. More broadly, interest in Fusion Antibodies Plc reflects the market’s search for evidence that management can translate activity into sustainableShareholdervalue. For this business, antibody discovery services and biotechnology customer spending matter …
No distinct company-specific catalyst for 4 November is established by the information reviewed. More broadly, interest in ImmuPharma plc reflects the market’s search for evidence that management can translate activity into sustainableShareholdervalue. For this business, drug development milestones and clinical funding matter because reported …
No distinct company-specific catalyst for 4 November is established by the information reviewed. More broadly, interest in Proteome Sciences plc reflects the market’s search for evidence that management can translate activity into sustainableShareholdervalue. For this business, proteomics services, biomarker research and contractRevenuematter because reported …
A third-quarter trading update was released on 3 November, placing commercial execution in focus. More broadly, interest in Shield Therapeutics Plc reflects the market’s search for evidence that management can translate activity into sustainableShareholdervalue. For this business, iron-deficiency treatment commercialisation and prescription uptake matter …
No distinct company-specific catalyst for 4 November is established by the information reviewed. More broadly, interest in Tristel Plc reflects the market’s search for evidence that management can translate activity into sustainableShareholdervalue. For this business, infection prevention products and international sales matter because reported …
Revenue was flat at US$206.0m (FY25: US$205.7m), while adjusted EBITDA rose 3% to US$67.1m and statutory profit before tax increased 7% to US$25.8m. (LSE:CRW) AnnualRecurring Revenuewas steady at about US$185m, and net revenue retention fell to 100% from 107%.
On the LSE delayed price for the 3 November session, captured shortly after midnight on 4 November, the shares were 23.4p, down 0.43%. (LSE:EKF) Using the 427,968,392 shares the company said would be in issue after its final buyback cancellation, that implies aMarket Valueof …
One of these, released by Octopus Investments at 12:40 on 3 November, showed that it sold 1,793,670 shares at £2.825 and a further 5,745 at £2.8275 on 2 November, leaving it with 12,388,798 shares, or 5.61%. (LSE:AMS) The form does not explain the reason …
Surgical Innovations designs and supplies minimally invasive surgical devices and is quoted on AIM, the London Stock Exchange's junior market. (LSE:SUN) Through 2025 and into 2026 the company issued trading updates and a chief financial officer update, and reported final results, keeping investors focused …